Luminex Co. (NASDAQ:LMNX) has been assigned an average recommendation of “Hold” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $20.00.

A number of research firms recently weighed in on LMNX. BidaskClub downgraded Luminex from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine upgraded Luminex from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Jefferies Group restated a “hold” rating and issued a $21.00 price target on shares of Luminex in a research note on Friday, October 20th. Zacks Investment Research upgraded Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 price target on the stock in a research note on Thursday, August 24th. Finally, TheStreet upgraded Luminex from a “c+” rating to a “b-” rating in a research note on Wednesday, November 1st.

Luminex (NASDAQ:LMNX) traded down $0.01 during trading hours on Thursday, hitting $20.55. The stock had a trading volume of 109,600 shares, compared to its average volume of 199,494. The firm has a market capitalization of $905.76, a price-to-earnings ratio of 35.45, a P/E/G ratio of 2.58 and a beta of 0.19. Luminex has a 1-year low of $17.68 and a 1-year high of $22.42.

Luminex (NASDAQ:LMNX) last released its earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.06. The business had revenue of $74.14 million for the quarter, compared to analyst estimates of $74.38 million. Luminex had a return on equity of 6.01% and a net margin of 9.52%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 earnings per share. research analysts expect that Luminex will post 0.49 earnings per share for the current year.

In other Luminex news, Director G Walter Loewenbaum II sold 50,000 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $21.79, for a total transaction of $1,089,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Algert Global LLC boosted its position in Luminex by 18.2% during the third quarter. Algert Global LLC now owns 129,997 shares of the medical instruments supplier’s stock worth $2,643,000 after purchasing an additional 20,043 shares in the last quarter. Neuberger Berman Group LLC raised its holdings in shares of Luminex by 9.6% in the third quarter. Neuberger Berman Group LLC now owns 1,015,916 shares of the medical instruments supplier’s stock worth $20,654,000 after acquiring an additional 89,141 shares during the last quarter. OxFORD Asset Management LLP raised its holdings in shares of Luminex by 4.3% in the third quarter. OxFORD Asset Management LLP now owns 194,526 shares of the medical instruments supplier’s stock worth $3,937,000 after acquiring an additional 7,964 shares during the last quarter. Elk Creek Partners LLC raised its holdings in shares of Luminex by 13.6% in the third quarter. Elk Creek Partners LLC now owns 871,429 shares of the medical instruments supplier’s stock worth $17,716,000 after acquiring an additional 104,494 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Luminex by 3.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,819,417 shares of the medical instruments supplier’s stock worth $36,989,000 after acquiring an additional 61,437 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/07/luminex-co-lmnx-receives-consensus-recommendation-of-hold-from-analysts.html.

Luminex Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.